Diana V. Messadi

Prof. Diana V. Messadi


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2013 in International Journal of Oral Science
Verified
Journal Article
Open access
PDF file
DMDiana V. Messadi
Diana V. Messadi
Oral cancer has a tendency to be detected at late stage which is detrimental to the patients because of its high mortality and morbidity rates. Early detection of oral cancer is therefore important to reduce the burden of this devastating disease. In this review article, the most common oral precancerous lesions are discussed and the importance of early diagnosis is emphasized. In addition, the most common non-invasive oral cancer devices that can aid the general practitioners in early diagnosis are also discussed.

1 May 2010 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
DMDiana V. Messadi
Diana V. Messadi
FYFariba Younai
Fariba Younai
Aphthous ulcers are one of the most common oral diseases worldwide. Their clinical presentation is characterized by multiple, recurrent, small, round, or ovoid ulcers with circumscribed margins and erythematous haloes present in different sizes. Oral lesions similar to aphthous ulcers may be present in several systemic diseases. This article will summarize the differential diagnosis of aphthous ulceration, with emphasis on a practical guide for the management of recurrent aphthous ulceration, including topical and systemic therapy.

1 May 2013 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
WAWilliam B. Armstrong
William B. Armstrong
TTThomas H. Taylor
Thomas H. Taylor
AKAnn R. Kennedy
Ann R. Kennedy
RMRaymond J. Melrose
Raymond J. Melrose
DMDiana V. Messadi
Diana V. Messadi
FMFrank L. Meyskens
Frank L. Meyskens
Oral premalignancy serves as an ideal model for study of chemopreventive agents. Although 13-cis-retinoic acid showed reversal of oral premalignancy, toxicity, and reversal of clinical response after cessation of therapy obviated its widespread use. A search for nontoxic agents with cancer preventive activity led us to evaluate Bowman Birk Inhibitor (BBI) formulated as BBI Concentrate (BBIC). We previously reported encouraging results in a phase IIa trial of BBIC in patients with oral leukoplakia with measurable clinical responses and favorable biomarker changes. On the basis of these results, we undertook a randomized, placebo controlled phase IIb trial with patients receiving BBIC or placebo for 6 months, with assessment of clinical response and change in lesion area as primary end point and an intent-to-treat analysis. One hundred and thirty two subjects were randomized; and 89 subjects completed six months on study drug or placebo. Both placebo and BBIC showed a statistically significant decrease in mean lesion area of 17.1% and 20.6%, respectively, and partial or greater clinical responses of 30% and 28% respectively. No significant difference between placebo and study drug arms was observed. Histologic review, review of photographs of lesions, and comparison of serum neu protein and oral mucosal cell protease activity also did not show significant differences between study arms. Probable reasons for these negative results were considered, are discussed, and include a placebo with non-BBIC clinical activity and reduced pharmacokinetic availability of the second batch of BBIC. This experience should be a strong cautionary note to those considering “Green” chemoprevention. Cancer Prev Res; 6(5); 410–8. ©2013 AACR.

25 July 2014 in International Journal of Oral Science
Verified
Journal Article
Open access
PDF file
DMDiana V. Messadi
Diana V. Messadi
FYFariba S Younai
Fariba S Younai
HLHong-Hu Liu
Hong-Hu Liu
GGGao Guo
Gao Guo
CWCun-Yu Wang
Cun-Yu Wang
Optical spectroscopy devices are being developed and tested for the screening and diagnosis of oral precancer and cancer lesions. This study reports a device that uses white light for detection of suspicious lesions and green–amber light at 545 nm that detect tissue vascularity on patients with several suspicious oral lesions. The clinical grading of vascularity was compared to the histological grading of the biopsied lesions using specific biomarkers. Such a device, in the hands of dentists and other health professionals, could greatly increase the number of oral cancerous lesions detected in early phase. The purpose of this study is to correlate the clinical grading of tissue vascularity in several oral suspicious lesions using the Identafi® system with the histological grading of the biopsied lesions using specific vascular markers. Twenty-one patients with various oral lesions were enrolled in the study. The lesions were visualized using Identafi® device with white light illumination, followed by visualization of tissue autofluorescence and tissue reflectance. Tissue biopsied was obtained from the all lesions and both histopathological and immunohistochemical studies using a vascular endothelial biomarker (CD34) were performed on these tissue samples. The clinical vascular grading using the green–amber light at 545 nm and the expression pattern and intensity of staining for CD34 in the different biopsies varied depending on lesions, grading ranged from 1 to 3. The increase in vascularity was observed in abnormal tissues when compared to normal mucosa, but this increase was not limited to carcinoma only as hyperkeratosis and other oral diseases, such as lichen planus, also showed increase in vascularity. Optical spectroscopy is a promising technology for the detection of oral mucosal abnormalities; however, further investigations with a larger population group is required to evaluate the usefulness of these devices in differentiating benign lesions from potentially malignant lesions.

7 April 2014 in Special Care in Dentistry
Verified
Journal Article
Closed access
PDF file
TATumouh Al‐Allaq
Tumouh Al‐Allaq
TDTerrie K. DeBord
Terrie K. DeBord
HLHonghu Liu
Honghu Liu
YWYan Wang
Yan Wang
DMDiana V. Messadi
Diana V. Messadi

25 March 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MZMin Zhang
Min Zhang
YCYang D Chai
Yang D Chai
JBJeffrey Brumbaugh
Jeffrey Brumbaugh
XLXiaojun Liu
Xiaojun Liu
RRRamin Rabii
Ramin Rabii
SHShen Hu
Shen Hu
Cancer cells may undergo metabolic adaptations that support their growth as well as drug resistance properties. The purpose of this study is to test if oral cancer cells can overcome the metabolic defects introduced by using small interfering RNA (siRNA) to knock down their expression of important metabolic enzymes.